Rituximab plus multiagent chemotherapy for newly diagnosed CD20-positive acute lymphoblastic leukemia: a prospective phase II study
Dong Won Baek, Han-Seung Park, Sang Kyun Sohn, Dae Young Kim, Inho Kim, Jae-Sook Ahn, Young Rok Do, Se Ryeon Lee, Hyeon-Seok Eom, Won-Sik Lee, Sung-Hyun Kim, Ho Sup Lee, Yoo Jin Lee, Joon Ho Moon, Je-Hwan Lee,
Korean J Intern Med. 2023;38(5):734-746. Published online 2023 Jun 20 DOI: https://doi.org/10.3904/kjim.2022.401
Citations to this article as recorded by 
Diagnostic and therapeutic advances in adults with acute lymphoblastic leukemia in the era of gene analysis and targeted immunotherapy
Jae-Ho Yoon, Seok Lee
The Korean Journal of Internal Medicine.2024; 39(1): 34. CrossRef
Prediction of Response to FDA-Approved Targeted Therapy and Immunotherapy in Acute Lymphoblastic Leukemia (ALL)
Zakaria Yahya Khawaji, Nussaiba Yahya Khawaji, Mohammed Abdullah Alahmadi, Abeer Abd Elmoneim
Current Treatment Options in Oncology.2024; 25(9): 1163. CrossRef
Clinical effect of prophylactic pegfilgrastim in patients with newly diagnosed acute lymphoblastic leukemia who receive intensive chemotherapy
Yunji Lee, Youngeun Jang, Jung Min Lee, Hee Jeong Cho, Joon Ho Moon, Sang Kyun Sohn, Ji Yeon Ham, Soon Hee Chang, Dong Won Baek
Supportive Care in Cancer.2024;[Epub] CrossRef
Prognostic Factors and Outcome of Patients with Adult Acute Lymphoblastic Leukemia Treated with the Hyper-CVAD Regimen: A Retrospective Study
Zahra Malakoutikhah, Farzaneh Ashrafi, Ali Derakhshandeh, Manishekhar Kumar
Advances in Hematology.2023; 2023: 1. CrossRef